On November 18, 2021 Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that data from a Phase 1 study investigating its MultiTAA-specific T cells were selected for oral presentation at the 2021 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Marker Therapeutics, NOV 18, 2021, View Source [SID1234595821]). The results will be reviewed by investigators at the Baylor College of Medicine, Marker’s research partner. ASH (Free ASH Whitepaper) will take place from December 11-14, 2021, in Atlanta and in a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details

Presentation Title: Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL (Abstract #471)
Session Title: 704. Cellular Immunotherapies: Cellular Therapies for ALL
Session Date/Time: Sunday, December 12, 2021, 12:30 p.m. ET
Presenting Author: Dr. Swati Naik, MBBS, Center for Cell and Gene Therapy, Baylor College of Medicine
Location: Georgia World Congress Center, B401-B402 and virtual

The abstract is available on the American Society of Hematology (ASH) (Free ASH Whitepaper) 2021 Annual Meeting website and in a supplement to the November issue of Blood, an ASH (Free ASH Whitepaper) journal.